FDA approves VEPPANU (vepdegestrant), the first PROTAC therapy for ESR1 mutated metastatic breast cancer. Approval sets a new treatment class for a genetic subgroup that has had limited targeted ...

Pfizer PFE and AstraZeneca AZN are two global pharmaceutical leaders with a commanding presence in oncology. For Pfizer, oncology is a key growth driver, accounting for roughly 27% of total company ...

Good news for Pfizer could be good news for AstraZeneca, for two reasons. First, President Trump hinted in the press conference earlier this week that other deals similar to Pfizer's could be on the ...

AstraZeneca’s first foray with PD-L1 inhibitor Imfinzi as a treatment for bladder cancer was a flop. | Following an FDA ...

An infectious disease expert has dismissed calls for more COVID vaccine makers to withdraw their jabs. Here’s why.

Pfizer ($PFE) appears to be speeding toward a crucial early FDA approval for palbociclib, a breast cancer treatment with blockbuster potential, pivoting from its ...

AstraZeneca PLC announced a deal with President Donald Trump that’s focused on lowering drug prices, in a move that would see the British drugmaker follow in the footsteps of Pfizer Inc. “Today, ...

LONDON (Reuters) -Wall Street is looking to U.S. drugmaker Eli Lilly and Anglo-Swedish rival AstraZeneca as the potential next in line after Pfizer struck a deal with Donald Trump's administration to ...

In my March article, "Why Pfizer Remains A Strong Buy In 2026", I mainly discussed Pfizer's Q4 earnings ( PFE) and the ...